{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:49:04Z","timestamp":1782244144321,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Objective: Our objectives were to describe molecular profiling in a real-life cohort of patients with radioiodine-resistant (RAI-R) differentiated or poorly differentiated thyroid cancer (DTC or PDTC) treated with lenvatinib and to focus on factors potentially influencing the quality of tissue samples for molecular analysis, including the impact of storage time, defined as the interval between tissue collection and molecular testing. Design: We retrospectively included all lenvatinib-treated RAI-R DTC or PDTC patients tested with DNA- and\/or RNA-based next-generation sequencing (NGS) in our center, also analyzing the results of fluorescence in situ hybridization (FISH) for RET fusions if the sample did not satisfy quality criteria for RNA-based NGS analysis. We investigated differences in terms of histotype, biopsy site, or storage time between adequate and inadequate samples for RNA-based NGS. Results: At least one gene alteration was detected in 50% of the cohort (18 out of 36 patients); RAS and BRAF were the most frequent mutations, while gene fusions accounted for 5.6% of cases. Tissue samples were more frequently adequate for DNA-based NGS compared to RNA-NGS analysis (93.9% vs. 58.3%, p &lt; 0.001). The median storage time was significantly longer in the case of inadequate samples for RNA-based NGS compared with adequate specimens (41.5 vs. 9.5 months, p = 0.016); samples archived for \u22653 years led more frequently to an inadequate result. Conclusions: Advanced RAI-R TC candidates for systemic therapy often harbor gene alterations. An adequate result was less frequently achieved in cases of RNA-based NGS than in DNA-based NGS, especially if the interval between tissue collection and molecular analysis was longer; nevertheless, the limited cohort size precludes definitive conclusions.<\/jats:p>","DOI":"10.3390\/curroncol33060372","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T18:35:05Z","timestamp":1782239705000},"page":"372","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Sequencing in Differentiated Thyroid Cancer Patients Treated with Lenvatinib: Results and Challenges in Real-Life Practice"],"prefix":"10.3390","volume":"33","author":[{"given":"Matteo","family":"Ferrari","sequence":"first","affiliation":[{"name":"Oncological Endocrinology Unit, Citt\u00e0 Della Salute E Della Scienza Hospital, Department of Medical Sciences, University of Turin, Via Genova 3, 10126 Turin, Italy"},{"name":"Division of Diabetology and Metabolic Disease, Department of Medicine, Azienda Sanitaria Locale Cuneo 1, 12100 Cuneo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Nervo","sequence":"additional","affiliation":[{"name":"Oncological Endocrinology Unit, Citt\u00e0 Della Salute E Della Scienza Hospital, Department of Medical Sciences, University of Turin, Via Genova 3, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Maletta","sequence":"additional","affiliation":[{"name":"Pathology Unit, Citt\u00e0 Della Salute E Della Scienza Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mariani","sequence":"additional","affiliation":[{"name":"Pathology Unit, Citt\u00e0 Della Salute E Della Scienza Hospital, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Oncological Endocrinology Unit, Citt\u00e0 Della Salute E Della Scienza Hospital, Department of Medical Sciences, University of Turin, Via Genova 3, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Piovesan","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Arvat","sequence":"additional","affiliation":[{"name":"Oncological Endocrinology Unit, Citt\u00e0 Della Salute E Della Scienza Hospital, Department of Medical Sciences, University of Turin, Via Genova 3, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-World Efficacy and Safety of Lenvatinib: Data from a Compassionate Use in the Treatment of Radioactive Iodine-Refractory Differentiated Thyroid Cancer Patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"bvac048","DOI":"10.1210\/jendso\/bvac048","article-title":"Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects","volume":"6","author":"Hamidi","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/thy.2020.0276","article-title":"Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer","volume":"31","author":"Giani","year":"2021","journal-title":"Thyroid"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial","volume":"35","author":"Brose","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2214","DOI":"10.1210\/clinem\/dgae107","article-title":"Clinically Relevant Germline Variants in Children With Nonmedullary Thyroid Cancer","volume":"109","author":"Ruano","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO Clinical Practice Guideline Update on the Use of Systemic Therapy in Advanced Thyroid Cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and Safety of Larotrectinib in Patients with TRK Fusion-Positive Thyroid Carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1\u20132 Trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e3353","DOI":"10.1210\/clinem\/dgaf056","article-title":"TP53 Alterations Are Associated with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer","volume":"110","author":"Cirello","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Minaldi, E., Ramone, T., Ciampi, R., Romei, C., Casalini, R., Gambale, C., Prete, A., Lorusso, L., Agate, L., and Torregrossa, L. (2026). Molecular Profile of Advanced Radioiodine-Refractory Thyroid Cancer and Response to Lenvatinib Treatment. J. Clin. Endocrinol. Metab., dgag074.","DOI":"10.1210\/clinem\/dgag074"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41698-026-01371-8","article-title":"Impact of BRAF, TERT, and Novel Mutations on the Efficacy of Lenvatinib for Advanced Papillary Thyroid Cancer: A National Genomic Database Analysis","volume":"10","author":"Sato","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12022-021-09665-2","article-title":"Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?","volume":"32","author":"Volante","year":"2021","journal-title":"Endocr. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group Consensus Statement on Mutational Testing in Thyroid Cancer: Defining Advanced Thyroid Cancer and Its Targeted Treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105856","DOI":"10.1016\/j.esmoop.2025.105856","article-title":"Impact of Molecular Tests and Precision Oncology on Patients with Advanced Thyroid Carcinomas in a Referral Center: The OrienTHYring Real-World Study","volume":"10","author":"Colombo","year":"2025","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Angerilli, V., Galuppini, F., Pagni, F., Fusco, N., Malapelle, U., and Fassan, M. (2021). The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics, 11.","DOI":"10.3390\/diagnostics11020339"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cappello, F., Angerilli, V., Munari, G., Ceccon, C., Sabbadin, M., Pagni, F., Fusco, N., Malapelle, U., and Fassan, M. (2022). FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. J. Pers. Med., 12.","DOI":"10.3390\/jpm12050750"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nibid, L., Sabarese, G., Andreotti, L., Canalis, B., Righi, D., Longo, F., Grazi, M., Crucitti, P., and Perrone, G. (2024). RNA-Seq Analysis in Non-Small Cell Lung Cancer: What Is the Best Sample from Clinical Practice?. J. Pers. Med., 14.","DOI":"10.3390\/jpm14080851"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Groelz, D., Viertler, C., Pabst, D., Dettmann, N., and Zatloukal, K. (2018). Impact of Storage Conditions on the Quality of Nucleic Acids in Paraffin Embedded Tissues. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203608"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yoo, S.-K., Lee, S., Kim, S., Jee, H.-G., Kim, B.-A., Cho, H., Song, Y.S., Cho, S.W., Won, J.-K., and Shin, J.-Y. (2016). Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1006239"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103704","DOI":"10.1016\/j.esmoop.2024.103704","article-title":"Corrigendum to \u201cClinical Relevance of Gene Mutations and Rearrangements in Advanced Differentiated Thyroid Cancer\u201d","volume":"9","author":"Nannini","year":"2024","journal-title":"ESMO Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e250089","DOI":"10.1530\/ERC-25-0089","article-title":"Next-Generation Sequencing of Targetable Gene Fusions in Radioiodine-Refractory Thyroid Cancer: A Multicenter Study","volume":"32","author":"Yoo","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00394-016-1370-2","article-title":"Iodine Intake as a Risk Factor for BRAF Mutations in Papillary Thyroid Cancer Patients from an Iodine-Replete Area","volume":"57","author":"Kim","year":"2018","journal-title":"Eur. J. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.annonc.2024.11.010","article-title":"Corrigendum to \u201cRecommendations for the Use of next-Generation Sequencing (NGS) for Patients with Advanced Cancer in 2024: A Report from the ESMO Precision Medicine Working Group\u201d: [Ann Oncol 35 (2024) 588-606]","volume":"36","author":"Mosele","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jmoldx.2011.11.002","article-title":"Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling","volume":"14","author":"Freidin","year":"2012","journal-title":"J. Mol. Diagn."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Guerrera, F., Tabb\u00f2, F., Bessone, L., Maletta, F., Gaudiano, M., Ercole, E., Annaratone, L., Todaro, M., Boita, M., and Filosso, P.L. (2016). The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0145100"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.anndiagpath.2013.02.001","article-title":"Analysis of the Effect of Various Decalcification Agents on the Quantity and Quality of Nucleic Acid (DNA and RNA) Recovered from Bone Biopsies","volume":"17","author":"Singh","year":"2013","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Eccher, A., Seminati, D., L\u2019Imperio, V., Casati, G., Pilla, D., Malapelle, U., Piga, I., Bindi, G., Marando, A., and Bonoldi, E. (2024). Pathology Laboratory Archives: Conservation Quality of Nucleic Acids and Proteins for NSCLC Molecular Testing. J. Pers. Med., 14.","DOI":"10.3390\/jpm14040333"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Pecciarini, L., Brunetto, E., Grassini, G., De Pascali, V., Ogliari, F.R., Talarico, A., Marra, G., Magliacane, G., Redegalli, M., and Arrigoni, G. (2023). Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?. Cells, 12.","DOI":"10.3390\/cells12081135"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO Recommendations on the Standard Methods to Detect NTRK Fusions in Daily Practice and Clinical Research","volume":"30","author":"Scaltriti","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Cancer Genome Atlas Research Network Integrated Genomic Characterization of Papillary Thyroid Carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/cge.13199","article-title":"Application of Next-Generation Sequencing to Improve Cancer Management: A Review of the Clinical Effectiveness and Cost-Effectiveness","volume":"93","author":"Tan","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","article-title":"Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan","volume":"109","author":"Toda","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","first-page":"23","article-title":"NTRK-Fusions in Pediatric Thyroid Tumors: Current State and Future Perspectives","volume":"264\u2013265","author":"Halada","year":"2022","journal-title":"Cancer Genet."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/372\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T19:29:59Z","timestamp":1782242999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060372"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060372","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]}}}